

Estimate change

TP change

Rating change



Motilal Oswal values your support in the
Asiamoney Brokers Poll 2020 for India
Research, Sales and Trading team.
We [request your ballot](#).



Bloomberg	SRF IN
Equity Shares (m)	59
M.Cap.(INRb)/(USDb)	209.7 / 2.9
52-Week Range (INR)	4259 / 2492
1, 6, 12 Rel. Per (%)	-9/29/40
12M Avg Val (INR M)	1062

Financials & Valuations (INR b)

Y/E Mar	2020	2021E	2022E
Sales	72.1	75.4	94.4
EBITDA	14.6	15.5	20.5
PAT	9.2	7.4	11.1
EBITDA (%)	20.2	20.5	21.7
EPS (INR)	157.2	125.7	189.9
EPS Gr. (%)	49.4	(20.0)	51.0
BV/Sh. (INR)	860	963	1,130

Ratios

Net D/E	0.7	0.6	0.5
RoE (%)	20.1	13.8	18.1
RoCE (%)	13.3	9.7	13.0
Payout (%)	9.6	18.5	12.2

Valuations

P/E (x)	23.2	29.0	19.2
EV/EBITDA (x)	17.2	16.1	12.0
Div Yield (%)	0.4	0.5	0.5
FCF Yield (%)	(1.7)	3.2	2.9

Shareholding pattern (%)

As On	Mar-20	Dec-19	Mar-19
Promoter	52.3	52.3	52.3
DII	11.3	11.6	11.6
FII	18.3	18.4	17.1
Others	18.1	17.7	19.0

Note: FII includes depository receipts

CMP: INR3,648
TP: INR4,244 (+16%)
Buy

Packaging business drives operating performance

Revenue/EBITDA below estimates; PAT in line

- 4QFY20 performance of SRF was impacted due to the COVID-19 pandemic and the auto sector slowdown, which in turn impacted the Technical Textiles and Refrigerant segments. However, strong margin expansion in the Packaging segment led to 4% EBITDA growth despite revenue decline of 4%.
- We have cut PAT estimates by 21%/4% for FY21/22E due to (a) lower demand for refrigerants on the slowdown in auto/white goods, and (b) the technical textiles business getting affected due to the auto slowdown.

COVID-19 drags Chemicals business' growth momentum

- Revenue declined 4% YoY to INR18.6b (v/s est. INR22.3b) while EBITDA grew 4% YoY to INR3.9b (v/s est. INR4.4b). PAT was up 22% YoY to INR2.2b (v/s est. INR2.3b) due to tax benefit during the quarter. For FY20, revenue/EBITDA/adj. PAT grew 2%/10%/49%.
- Chemicals** revenue grew 5% YoY to INR8.8b with EBIT margin contraction of 170bp YoY to 18% (EBIT grew 4%). The segment's performance was impacted by COVID-19, otherwise it has been consistently reporting >25% revenue growth since 1QFY19. Additionally, fluorochemicals' performance was impacted by the auto slowdown and drop in global prices of refrigerants.
- Packaging film** revenues declined 3% YoY to INR6b with margin expansion of 480bp YoY to 21.7% (EBIT grew 24% YoY). Margin expansion was on account of product mix and the demand/supply scenario.
- Technical Textiles'** revenue declined by a significant 22% YoY to INR3.2b due to slump in the automotive sector. Segmental margins were flat YoY to 11.7%. SRF saw inventory loss of INR30-40m due to fall in caprolactam prices.

Highlights from management commentary

- Management remains confident of achieving 20-25% revenue growth in FY21 for specialty chemicals on a high base. The company achieved 59% growth in FY20 (to INR16.5b), which is commendable, in our view.
- 4-5 new BOPET lines with capacity of 38-40kMT each have been commissioned (accounts for ~5% of global supply), which may impact packaging segment margins in FY21.
- In May'20, SRF commissioned BOPET film line of 40kMT in Thailand at a capex of USD51m. Commissioning of the BOPET plant in Hungary has been delayed due to the COVID-19 pandemic, but should commence in Jul'20.

Valuation and view

- Performance in 4QFY20 was impacted due to the COVID-19 pandemic and the auto slowdown. While sluggishness in the auto sector dented performance of the technical textiles business, the slowdown in white goods/auto impacted the refrigerants business.
- Additionally, packaging film margins are also likely to moderate in FY21 owing to oversupply.

Research Analyst: **Sumant Kumar** (Sumant.Kumar@MotilalOswal.com); +91 22 6129 1569

Darshit Shah (Darshit.Shah@motilaloswal.com); +9122 6129 1546 / **Yusuf Inamdar** (yusuf.inamdar@motilaloswal.com); +91 22 7193 4239

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

- However, on the positive side, management remains confident of achieving 20-25% revenue growth in the specialty chemicals segment (forms 23% of FY20 sales).
- Also, increase in replacement demand for the auto sector (when normalcy is achieved) should boost performance of technical textiles/refrigerants. Factoring in the same, we have cut our PAT estimates by 21%/4% for FY21/22E. We value SRF on an SOTP basis to arrive at a target price of INR4,244. Maintain **Buy**.

Consolidated - Quarterly Earning Model

(INR Million)


Y/E March	FY19				FY20				FY19	FY20	FY20	Var
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			4QE	%
Net Sales	16,762	17,550	18,088	19,370	17,633	17,378	18,505	18,578	71,769	72,094	22,277	-17
YoY Change (%)	29.6	36.4	29.5	20.1	5.2	-1.0	2.3	-4.1	28.4	0.5	10.6	
Total Expenditure	13,576	14,375	14,968	15,630	14,186	14,026	14,603	14,695	58,549	57,510	17,874	
EBITDA	3,186	3,175	3,120	3,740	3,447	3,352	3,902	3,884	13,221	14,584	4,402	-12
Margins (%)	19.0	18.1	17.2	19.3	19.5	19.3	21.1	20.9	18.4	20.2	19.8	
Depreciation	879	877	909	949	925	929	1,019	1,014	3,614	3,886	1,030	
Interest	442	491	534	524	515	550	475	466	1,990	2,007	500	
Other Income	38	29	65	161	152	220	56	63	294	491	149	
PBT before EO expense	1,904	1,836	1,741	2,428	2,159	2,093	2,463	2,467	7,909	9,182	3,021	
Extra-Ord expense	103	-52	-226	-100	-289	-960	-103	355	-275	-997	0	
PBT	1,801	1,889	1,967	2,528	2,448	3,053	2,566	2,112	8,184	10,179	3,021	
Tax	462	377	310	619	554	41	-864	255	1,768	-14	760	
Rate (%)	24.3	20.5	17.8	25.5	25.7	2.0	-35.1	10.3	22.4	-0.2	25.2	
Reported PAT	1,338	1,512	1,657	1,909	1,894	3,011	3,430	1,857	6,416	10,193	2,261	
Adj PAT	1,441	1,460	1,431	1,809	1,605	2,051	3,327	2,212	6,141	9,196	2,261	-2
YoY Change (%)	56.0	53.1	29.9	54.0	11.3	40.5	132.5	22.3	47.8	49.7	19.6	
Margins (%)	8.6	8.3	7.9	9.3	9.1	11.8	18.0	11.9	8.6	12.8	10.1	

Key Performance Indicators

Y/E March	FY19				FY20				FY19	FY20
Consolidated	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q		
Segment Revenue Growth (%)										
Technical Textile	-1.2	8.7	0.5	-12.5	-23.8	-28.8	-26.1	-21.6	-1.4	-25.1
Chemicals & Polymers	33.8	56.6	45.8	65.8	26.4	25.1	38.5	5.0	51.8	21.7
Packaging Film	52.3	69.5	63.3	18.3	11.1	-4.8	-9.2	-3.5	48.9	-1.9
Segment EBIT Margins (%)										
Technical Textile	14.4	15.3	16.0	11.8	14.9	6.5	10.9	11.7	14.4	11.2
Chemicals & Polymers	16.5	11.6	13.1	19.8	13.0	19.3	17.6	18.0	15.7	17.2
Packaging Film	15.4	17.3	12.5	17.0	20.7	19.6	23.4	21.7	15.5	21.3
Cost Break-up										
RM Cost (% of sales)	55.0	57.0	56.7	55.2	54.1	50.8	50.4	49.4	56.0	51.1
Staff Cost (% of sales)	7.0	6.4	6.5	6.5	7.3	7.4	7.4	7.9	6.6	7.5
Power and Fuel Cost (% of sales)	8.8	8.6	8.1	7.6	8.8	9.4	9.8	9.2	8.3	9.3
Other Cost (% of sales)	10.2	9.9	11.5	11.4	10.3	13.0	11.3	12.6	10.8	11.8
Gross Margins (%)	45.0	43.0	43.3	44.8	45.9	49.2	49.6	50.6	44.0	48.9
EBITDA Margins (%)	19.0	18.1	17.2	19.3	19.5	19.3	21.1	20.9	18.4	20.2
EBIT Margins (%)	13.8	13.1	12.2	14.4	14.3	13.9	15.6	15.4	13.4	14.8


Key Exhibits

Exhibit 1: Consolidated revenue trend




Source: Company, MOFSL

Exhibit 2: Consolidated EBITDA trend




Source: Company, MOFSL

Exhibit 3: Consolidated adj. PAT trend




Source: Company, MOFSL

Exhibit 4: Revenue mix trend




Source: Company, MOFSL

Exhibit 5: EBIT mix trend




Source: Company, MOFSL

Exhibit 6: Chemicals revenue trend




Source: Company, MOFSL

Exhibit 7: Chemicals EBIT trend




Source: Company, MOFSL

Exhibit 8: Packaging films revenue trend




Source: Company, MOFSL

Exhibit 9: Packaging films EBIT trend




Source: Company, MOFSL

Exhibit 10: Technical textiles revenue trend



Source: Company, MOFSL

Exhibit 11: Technical textiles EBIT trend



Source: Company, MOFSL



Conference call highlights

Specialty Chemicals

- SRF faced logistics issues during the quarter, which led to delay in product delivery.
- Due to COVID-19, production facilities were completely closed for 15 days; from mid-Apr'20, operations started in a phased manner.
- **Achieved revenue of INR16.5b in the specialty chemicals segment and have guided for 20-25% growth in FY21.**
- Order-book looks strong, as growth is expected in agro and pharma segment.

Fluorochemicals

- Performance in the segment was subdued due to prolong and severe slowdown in auto/white goods sector, leading to lower demand.
- **Price of key refrigerants was low during the quarter. Demand for refrigerant from OEMs is expected to be muted in the near term. Slight pull is expected from the replacement market on lifting up of the lockdown.**
- The recently commissioned HFC capacity is expected to ramp up volumes over the next few quarters.
- Volumes of chloromethane contributed to the segment's growth. Prices of certain chloromethane products contracted, resulting in a quick shift to other products.
- **Capacity utilization in the refrigerant segment is 70-75% for FY20 (on pro-rata basis).**

Packaging

- Delivered strong performance in BOPP and BOPET due to improvement in volumes and product-mix. In India and internationally, plants were operating at optimum utilization level.
- During the lockdown, all plants were operational and functioning at reasonable capacity.
- **Operating margins should moderate as new lines in the international market are expected to impact the demand-supply scenario.**
- In May'20, SRF commissioned the BOPET film line of 40kMT in Thailand at a capex of USD51m. Commissioning of the BOPET plant in Hungary has been delayed due to COVID-19, but should commence in Jul'20.
- Growth from value-added products was 20-22% in FY20.

Technical Textiles

- Performance of Tyre Cord Fabric business was severely impacted due to sluggish domestic demand.
- Inventory loss of INR30-40m due to fall in caprolactam prices.
- OEM demand may take a longer time to recover, whereas replacement demand is expected to kick-in by end of 2QFY21.
- Coated and Laminated fabrics business reported stable performance led by new product launches. Laminated margins were affected due to oversupply in the market.

Others

- Tax rate was lower in FY20 as the company recognized INR1.8b as income tax benefit during the year. This is a one-time deferred re-measurement exercise carried out in view of the Income Tax Ordinance.
- The company has enough land at its disposal to expand for the next three years.
- **Blended cost of debt is 3.5-3.75%.**
- **Net debt was higher by INR3b in FY20. Target is to reduce net debt by INR2-3b in FY21; however, it may change depending on capex.**
- Capex of INR8b for FY21 (excluding BOPP and resin plant in Thailand and BOPET plant in Hungary).

Valuation and view

- Performance in 4QFY20 was impacted due to the COVID-19 pandemic and the auto slowdown. While sluggishness in the auto sector dented performance of the technical textiles business, the slowdown in white goods/auto impacted the refrigerants business.
- Additionally, packaging film margins are also likely to moderate in FY21 owing to oversupply.
- However, on the positive side, management remains confident of achieving 20-25% revenue growth in the specialty chemicals segment (forms 23% of FY20 sales).
- Also, increase in replacement demand for the auto sector (when normalcy is achieved) should boost performance of technical textiles/refrigerants. Factoring in the same, we have cut our PAT estimates by 21%/4% for FY21/22E. We value SRF on an SOTP basis to arrive at a target price of INR4,244. Maintain **Buy**.

Valuation Methodology

EV/EBITDA	FY22 EBITDA (INRm)	Multiple (x)	EV (INRm)
Technical Textiles	1,973	7	13,810
Chemicals & Polymers	12,056	17	2,04,953
Packaging Films	7,598	8	60,785
Others	320	5	1,599
Total EV			2,81,148
Less: Debt			34,740
Less: Minority Interest			-
Add: Cash & Cash Equivalents			1,880
Target Mcap (INR mn)			2,48,288
Outstanding share (mn)			58.5
Target Price (INR)			4,244
CMP (INR)			3,648
Upside (%)			16%

Source: MOFSL

Exhibit 12: Change in estimates

Earnings Change (INR m)	Old		New		Change	
	FY21E	FY22E	FY21E	FY22E	FY21E	FY22E
Revenue	85,240	98,284	75,359	94,406	-12%	-4%
EBITDA	17,537	20,596	15,450	20,488	-12%	-1%
Adj. PAT	9,285	11,535	7,355	11,108	-21%	-4%

Source: MOFSL

Financials and valuations

Consolidated - Income Statement

(INR Million)

Y/E March	FY16	FY17	FY18	FY19	FY20	FY21E	FY22E
Total Income from Operations	45,927	48,218	55,890	70,996	72,094	75,359	94,406
Change (%)	1.2	5.0	15.9	27.0	1.5	4.5	25.3
Total Expenditure	36,199	38,524	46,828	57,787	57,510	59,908	73,918
% of Sales	78.8	79.9	83.8	81.4	79.8	79.5	78.3
EBITDA	9,728	9,694	9,062	13,209	14,584	15,450	20,488
Margin (%)	21.2	20.1	16.2	18.6	20.2	20.5	21.7
Depreciation	2,750	2,834	3,158	3,582	3,886	4,168	4,472
EBIT	6,979	6,859	5,904	9,627	10,698	11,282	16,016
Int. and Finance Charges	1,305	1,018	1,239	1,984	2,007	2,144	1,993
Other Income	278	730	688	280	491	540	594
PBT bef. EO Exp.	5,952	6,572	5,353	7,923	9,182	9,677	14,616
EO Items	-103	0	463	262	997	0	0
PBT after EO Exp.	5,849	6,572	5,817	8,185	10,179	9,677	14,616
Current Tax	1,551	1,422	1,200	1,769	265	2,323	3,508
Deferred Tax	0	0	0	0	-277	0	0
Tax Rate (%)	26.5	21.6	20.6	21.6	-0.1	24.0	24.0
Less: Mionrity Interest	0	0	0	0	0	0	0
Reported PAT	4,299	5,150	4,617	6,416	10,191	7,355	11,108
Adjusted PAT	4,402	5,150	4,154	6,155	9,194	7,355	11,108
Change (%)	45.4	17.0	-19.3	48.2	49.4	-20.0	51.0
Margin (%)	9.6	10.7	7.4	8.7	12.8	9.8	11.8

Consolidated - Balance Sheet

(INR Million)

Y/E March	FY16	FY17	FY18	FY19	FY20	FY21E	FY22E
Equity Share Capital	584	584	584	585	585	585	585
Preference Capital	0	0	0	0	0	0	0
Total Reserves	27,045	31,242	35,061	40,708	49,748	55,746	65,497
Net Worth	27,630	31,827	35,645	41,293	50,333	56,331	66,082
Minority Interest	0	0	0	0	0	0	0
Deferred Liabilities	3,820	2,866	2,914	3,420	1,755	1,755	1,755
Total Loans	25,153	23,962	31,418	36,993	40,240	37,740	34,740
Capital Employed	56,603	58,655	69,978	81,706	92,328	95,825	1,02,576
Gross Block	71,410	77,169	87,502	95,962	1,05,188	1,14,188	1,21,188
Less: Accum. Deprn.	30,334	33,169	36,327	39,908	43,795	47,963	52,435
Net Fixed Assets	41,076	44,000	51,175	56,053	61,394	66,226	68,754
Goodwill on Consolidation	49	49	41	41	41	41	41
Capital WIP	1,174	2,586	5,588	7,536	13,933	11,933	11,933
Current Investments	1,606	1,708	1,217	1,005	1,985	0	0
Total Investments	1,649	1,959	1,218	1,006	2,027	2,027	2,027
Curr. Assets, Loans&Adv.	20,291	21,090	25,608	34,243	32,373	34,607	42,005
Inventory	6,711	8,381	9,582	12,247	12,012	10,570	12,556
Account Receivables	5,145	6,569	6,807	10,288	8,911	9,291	11,639
Cash and Bank Balance	3,399	961	967	1,989	1,255	2,001	1,880
Loans and Advances	5,036	5,178	8,252	9,719	10,196	12,745	15,931
Curr. Liability & Prov.	8,934	11,055	13,653	17,173	17,440	19,007	22,182
Account Payables	7,146	8,089	10,442	13,824	11,117	12,684	15,860
Other Current Liabilities	1,477	2,606	2,831	2,908	5,881	5,881	5,881
Provisions	312	359	380	441	442	442	442
Net Current Assets	11,357	10,035	11,955	17,070	14,934	15,599	19,823
Deferred Tax assets	1,297	26	0	0	0	0	0
Misc Expenditure	0	0	0	0	0	0	0
Appl. of Funds	56,603	58,655	69,978	81,706	92,328	95,825	1,02,576

Financials and valuations

Ratios

Y/E March	FY16	FY17	FY18	FY19	FY20	FY21E	FY22E
Basic (INR)							
EPS	75.3	88.1	71.1	105.2	157.2	125.7	189.9
Cash EPS	122.4	136.6	125.1	166.4	223.6	197.0	266.3
BV/Share	472.8	544.6	609.9	705.9	860.4	962.9	1,129.6
DPS	9.8	11.8	16.0	20.0	14.0	20.0	20.0
Payout (%)	15.5	15.9	23.5	21.2	9.6	18.5	12.2
Valuation (x)							
P/E	48.4	41.4	51.3	34.7	23.2	29.0	19.2
Cash P/E	29.8	26.7	29.2	21.9	16.3	18.5	13.7
P/BV	7.7	6.7	6.0	5.2	4.2	3.8	3.2
EV/Sales	5.1	4.9	4.3	3.5	3.5	3.3	2.6
EV/EBITDA	24.0	24.2	26.8	18.7	17.2	16.1	12.0
Dividend Yield (%)	0.3	0.3	0.4	0.5	0.4	0.5	0.5
FCF per share	58.9	19.0	-110.5	-44.4	-61.2	115.3	106.5
Return Ratios (%)							
EBITDA Margins (%)	21.2	20.1	16.2	18.6	20.2	20.5	21.7
Net Profit Margins (%)	9.6	10.7	7.4	8.7	12.8	9.8	11.8
RoE	17.0	17.3	12.3	16.0	20.1	13.8	18.1
RoCE	10.5	11.0	8.5	10.7	13.3	9.7	13.0
RoIC	18.5	17.8	13.8	18.1	15.3	18.9	24.7
Working Capital Ratios							
Fixed Asset Turnover (x)	0.6	0.6	0.6	0.7	0.7	0.7	0.8
Asset Turnover (x)	0.8	0.8	0.8	0.9	0.8	0.8	0.9
Inventory (Days)	105	126	115	113	119	100	95
Debtor (Days)	41	50	44	53	45	45	45
Creditor (Days)	112	122	126	127	110	120	120
Leverage Ratio (x)							
Debt/Equity	0.9	0.8	0.9	0.9	0.8	0.7	0.5

Consolidated - Cash Flow Statement

(INR Million)

Y/E March	FY16	FY17	FY18	FY19	FY20	FY21E	FY22E
OP/(Loss) before Tax	5,952	6,572	5,817	8,185	10,179	9,677	14,616
Depreciation	2,750	2,834	3,158	3,582	3,886	4,168	4,472
Interest & Finance Charges	1,305	1,018	1,239	1,984	2,007	2,144	1,993
Direct Taxes Paid	-1,551	-1,422	-1,200	-1,769	-265	-2,323	-3,508
(Inc)/Dec in WC	703	-2,464	-2,138	-4,171	-3,762	80	-4,344
CF from Operations	9,159	6,538	6,876	7,811	12,044	13,748	13,229
Others	-947	1,742	0	0	0	0	0
CF from Operating incl EO	8,212	8,280	6,876	7,811	12,044	13,748	13,229
(inc)/dec in FA	-4,771	-7,170	-13,335	-10,408	-15,624	-7,000	-7,000
Free Cash Flow	3,441	1,110	-6,460	-2,597	-3,579	6,748	6,229
(Pur)/Sale of Investments	0	0	0	212	-1,021	0	0
Others	-707	-310	741	0	4,841	0	0
CF from Investments	-5,477	-7,479	-12,595	-10,196	-11,803	-7,000	-7,000
Issue of Shares	0	0	0	1	0	0	0
Inc/(Dec) in Debt	1,053	-1,523	7,806	5,575	3,246	-2,500	-3,000
Interest Paid	-1,305	-1,018	-1,239	-1,984	-2,007	-2,144	-1,993
Dividend Paid	-664	-821	-1,085	-1,357	-983	-1,357	-1,357
Others	507	123	243	1,171	-1,232	0	0
CF from Fin. Activity	-409	-3,238	5,726	3,406	-975	-6,002	-6,350
Inc/Dec of Cash	2,326	-2,438	6	1,021	-734	746	-121
Opening Balance	1,073	3,399	961	968	1,989	1,255	2,001
Closing Balance	3,399	961	968	1,989	1,255	2,001	1,880

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Investment Advisory Services, Depository participant services & distribution of various financial products. MOFSL is a subsidiary company of Passionate Investment Management Pvt. Ltd.. (PIMPL). MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act") and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co.Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company
- received compensation/other benefits from the subject company in the past 12 months
- other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 71934200/ 022-71934263; Website www.motilaloswal.com.CIN no.: L67190MH2005PLC153397. Correspondence Office Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad(West), Mumbai- 400 064. Tel No: 022 7188 1000.

Registration Nos.: Motilal Oswal Financial Services Limited (MOFSL)*: INZ000158836(BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412. AMFI: ARN - 146822; Investment Adviser: INA000007100; Insurance Corporate Agent: CA0579;PMS:INP000006712. Motilal Oswal Asset Management Company Ltd. (MOAMC): PMS (Registration No.: INP000000670); PMS and Mutual Funds are offered through MOAMC which is group company of MOFSL. Motilal Oswal Wealth Management Ltd. (MOWML): PMS (Registration No.: INP000004409) is offered through MOWML, which is a group company of MOFSL. Motilal Oswal Financial Services Limited is a distributor of Mutual Funds, PMS, Fixed Deposit, Bond, NCDs, Insurance Products and IPOs. Real Estate is offered through Motilal Oswal Real Estate Investment Advisors II Pvt. Ltd. which is a group company of MOFSL. Private Equity is offered through Motilal Oswal Private Equity Investment Advisors Pvt. Ltd which is a group company of MOFSL. Research & Advisory services is backed by proper research. Please read the Risk Disclosure Document prescribed by the Stock Exchanges carefully before investing. There is no assurance or guarantee of the returns. Investment in securities market is subject to market risk, read all the related documents carefully before investing. Details of Compliance Officer: Name: Neeraj Agarwal, Email ID: na@motilaloswal.com, Contact No.:022-71881085.

* MOSL has been amalgamated with Motilal Oswal Financial Services Limited (MOFSL) w.e.f August 21, 2018 pursuant to order dated July 30, 2018 issued by Hon'ble National Company Law Tribunal, Mumbai Bench.